Catalytic Strategies in Oncology and Autoimmunity: From EGFR Resistance to RNA-Guided Screening

Recent advances showcase catalytic and selective strategies that move beyond conventional inhibition or immunosuppression. These include degraders targeting resistant EGFR, antibodies depleting CD7+ pathogenic lymphocytes, ADAR-based RNA sensors for drug discovery, and quinazoline inhibitors penetrating the brain to block C797X double mutants. Together, these platforms illustrate convergent approaches to dismantle disease drivers at protein, immune, RNA, and signaling levels.